Larazotide Acetate (also known as AT-1001) is a synthetic octapeptide that acts on the tight junctions between intestinal cells. These tight junctions regulate what enters the bloodstream from the gut. When disrupted — as in cases of leaky gut or celiac disease — toxins, undigested food particles, and pathogens can pass through and trigger systemic inflammation.Larazotide works by inhibiting zonulin, a protein that loosens tight junctions in response to stress, gluten, or infection. By stabilizing the gut barrier, it reduces the translocation of inflammatory triggers and lowers systemic immune activation.It has been tested in phase II clinical trials for celiac disease, where it was shown to reduce gluten-induced symptoms and improve intestinal integrity without suppressing the immune system.
This makes Larazotide a unique option for:
- Managing gut permeability
- Supporting autoimmune conditions
- Improving tolerance to food antigens
- Reducing neuroinflammation and skin flare-ups tied to gut dysfunction
References
Leffler, D. A. et al. (2015). “A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.” Alimentary Pharmacology & Therapeutics, 42(2), 273–285.
Fasano, A. (2012). “Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer.” Physiological Reviews, 91(1), 151–175.
